Pharmaceutical industry – Page 58
-
Business
US approves new anaemia drug
US authorities have approved Omontys (peginesatide) injections for treating anaemia in dialysis patients with chronic kidney disease
-
Business
PCSK9 inhibitors against cholesterol problems perform well
Sanofi has reported Phase II data for a new drug candidate for lowering cholesterol levels in patients already taking statins
-
Business
$500m for Ista
US eye drug company Bausch & Lomb has signed a cash deal to buy US drugmaker Ista Pharmaceuticals for $9.10 per share, equivalent to $500 million
-
Business
Court throws out patent covering drug dosing
The US Supreme Court has said that medical tests that rely on correlations between drug doses and treatment cannot be patented
-
Business
AbbVie emerges from Abbott split
US healthcare giant Abbott has renamed the branded drugs part of its business
-
Business
GSK to build £350m factory in UK
GlaxoSmithKline (GSK) has announced £350 million plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria
-
News
GSK to build £350 million factory in UK
Tax breaks in the UK budget have prompted GSK to reaffirm its commitment
-
News
India green lights production of patented cancer drug
For the first time India has invoked a ‘compulsory licence’ clause to cut the cost of a patented anti-cancer drug
-
CareersThe future of medicine
A medicinal chemistry course that’s giving students a real taste of pharma - failure, frustration and all
-
OpinionThe elements of drug design
Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
-
Opinion
The language of the lab
Derek Lowe wonders what the lab lingua franca might be in the years to come
-
Opinion
Rewards of repurposing
Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
-
-
Opinion
Compounds in the dark
Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature
-
OpinionCommon sense and safety
You have to make space for good sense when thinking about safety, argues Derek Lowe
-
Opinion'Pay for delay'
Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
-
OpinionThe pitfalls that prevent progress
Derek Lowe highlights the less visible pitfalls on the road to a new drug
-
OpinionThe financial funfair
The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?
-
OpinionCategorising chemists
To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe
-
OpinionWho counts as a chemist?
The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country